Evidence map›Paper›PMID 40697653›Full record

SynthesisFrontiers in pharmacology2025

Therapeutic potential of quercetin in depressive symptoms: a systematic review and meta-analysis of preclinical studies.

Yang Yang, Yingshi Zhang, Lixin Chen, Ze Li, Qingchun Zhao

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yang YangSchool of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
Yingshi ZhangSchool of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
Lixin ChenDepartment of Pharmacy, Jinqiu Hospital of Liaoning Province, Shenyang, Liaoning, China.
Ze LiDepartment of Pharmacy, Jinqiu Hospital of Liaoning Province, Shenyang, Liaoning, China.
Qingchun ZhaoSchool of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Depression is a common and severe mental disorder. Quercetin, a natural flavonoid compound, has been shown in several studies through animal experiments to improve depressive symptoms, demonstrating significant antidepressant potential. Objective: This study represents the first preclinical meta-analysis on quercetin and depression, aiming to systematically evaluate the antidepressant effects of quercetin in animal studies. Methods: This study conducted a systematic search of the PubMed, EMBASE, Cochrane Library, and Web of Science electronic databases, with the search period covering from the inception of the databases to January 2025. Subsequently, the SYRCLE risk of bias assessment tool was used for quality evaluation, and data analysis was performed using RevMan 5.4 software. Results: This systematic review included 52 animal studies for random-effects meta-analysis. The results indicated that, compared to the control group, quercetin significantly reduced the immobility time in the forced swimming test and tail suspension test, as well as the time spent in the closed arms of the elevated plus maze. Simultaneously, it increased sucrose preference, swimming time in the forced swimming test, total distance traveled in the open field test, time spent in the central area, and the number of entries into the central area. In the elevated plus maze test, quercetin also increased the time spent in the open arms and the number of entries into the open arms. However, it did not produce a significant effect on the number of standing episodes in the open field test. Moreover, quercetin increased the levels of glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and brain-derived neurotrophic factor (BDNF), while reducing the levels of malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and corticosterone (CORT). Conclusion: This meta-analysis indicates that quercetin significantly improves depressive symptoms. However, further high-quality studies are needed to explore the role of quercetin in antidepressant research. Systematic Review Registration: http://inplasy.com/, Identifier: INPLASY202530047.

Indexed as

depressionmeta-analysispreclinical studiesquercetinsystematic review

Identifiers

PMID40697653
PMCPMC12280726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.